BRIEF-Conduent Announces Agreement To Sell Its Casualty Claims Solutions Business To Medrisk-June 2024-www.financetom.com

BRIEF-Conduent Announces Agreement To Sell Its Casualty Claims Solutions Business To Medrisk

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Conduent Announces Agreement To Sell Its Casualty Claims Solutions Business To Medrisk

May 3, 2024 6:41 AM

May 3 (Reuters) - Conduent Inc ( CNDT ):

* CONDUENT ANNOUNCES AGREEMENT TO SELL ITS CASUALTY CLAIMS

SOLUTIONS BUSINESS TO MEDRISK

* CONDUENT INC ( CNDT ): SALE, FOR $240 MILLION IN CASH

* CONDUENT INC ( CNDT ) - AS PART OF THIS TRANSACTION, CURRENT

CONDUENT

EMPLOYEES IN CASUALTY CLAIMS SOLUTIONS BUSINESS WILL JOIN

MEDRISK

* CONDUENT INC ( CNDT ) - CONDUENT WILL CONTINUE TO PROVIDE MAILROOM

SERVICES FOR CURRENT CASUALTY CLAIMS CLIENTS INCLUDING MEDRISK

Source text for Eikon:

Further company coverage:

Previous page： Central Garden & Pet Increases Share Buyback Plan Next page： Merck Discontinues Vibostolimab, Favezelimab Clinical Trials

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Central Garden & Pet Increases Share Buyback Plan

Dec 16, 2024

05:13 PM EST, 12/16/2024 (MT Newswires) -- Central Garden & Pet ( CENT ) said Monday its board has approved a $100 million increase in its authorization to repurchase shares, bringing total repurchase authorization to about $130 million. The share repurchase program does not have an expiration date, the firm said. ...

Merck Discontinues Vibostolimab, Favezelimab Clinical Trials

Dec 16, 2024

05:13 PM EST, 12/16/2024 (MT Newswires) -- Merck ( MRK ) said Monday it is discontinuing the clinical development programs for vibostolimab and favezelimab. Merck ( MRK ) said it is ending Phase 3 trials in the KeyVibe program, which assesses the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell lung cancer, based on the recommendation...

Perpetual-KKR deal not best for shareholders after tax bill blowout, says board expert

Dec 16, 2024

Dec 17 (Reuters) - Perpetual on Tuesday said the independent expert of the firm has opined that the asset manager's plan to sell wealth management and corporate trust business to KKR would not serve best interest of investors after tax bill blowout. The company's A$2.2 billion ($1.40 billion) deal with the buyout giant is at risk of falling after the...

Compass Minerals International Fiscal Q4 Adjusted Loss Widens, Sales Decline; Share Down After Hours

Dec 16, 2024

05:10 PM EST, 12/16/2024 (MT Newswires) -- Compass Minerals International ( CMP ) reported a fiscal Q4 adjusted loss late Monday of $0.77 per diluted share, widening from a loss of $0.10 a year earlier. Four analysts polled by FactSet expected a per-share non-GAAP loss of $0.49. Sales for the quarter ended Sept. 30 totaled $208.8 million, down from $233.6...